Care Research Inc — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$1,022,238	252
2024	Research	$958,336	129
2023	Research	$197,692	5

Breakdown

Who paid Research payments · program years 2023–2025

Teva Pharmaceuticals USA, Inc. $1,113,228 57 payments
ITI, Inc. $445,469 212 payments
Pfizer Inc. $379,312 16 payments
Incyte Corporation $137,235 9 payments
Takeda Pharmaceuticals U.S.A., Inc. $103,021 92 payments

Studies the money was for Research payments · program years 2023–2025

A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma $1,033,040 49 payments
A Phase 23 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Vaccine Candidates for Sarscov2 New Variants in Healthy Individuals $365,212 12 payments
Iti-007-602 $265,050 145 payments
Iti-007-321 $170,521 65 payments
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma $137,235 9 payments
A Phase 4, Multicenter, 2-Part Study Composed of A 1-Year Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Comparator, Dose-Optimization Evaluation Followed By A 1-Year Open-Label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-Release (Spd503) in Children and Adolescents Aged 6 to 17 Years With Attention-Deficit/Hyperactivity Disorder $103,021 92 payments
An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler with e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants with Asthma (4 to 11 Years Old) $79,983 7 payments
A Phase 3 Placebocontrolled Doubleblinded Randomized Study to Evaluate the Efficacy Safety and Tolerability of A Clostridioides Difficile Vaccine in Adults 65 Years of Age and Older $11,446 3 payments
Iti-007-421 $9,898 2 payments
A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $2,654 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.